Clinical Trial

CAN1012 in Pre-Malignant DCIS and LCIS

Name: CAN1012 in Pre-Malignant DCIS and LCIS — clinical trial record (NCT07408856)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Protocol Amendment History 2 changes

notable Enrollment reduced: 60 -> 24 participants 2026-04-09

minor Trial arms changed: 3 -> 4 2026-04-09

Trial Details

NCT Number	NCT07408856
Lead Sponsor	Providence Health & Services Collaborators: CanWell Pharma Inc.
Conditions	Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
Enrollment	24 participants
Start Date	2026-08
Primary Completion	2030-05 (estimated)
Study Completion	2035-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-23